3979 related articles for article (PubMed ID: 29097493)
1. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
[TBL] [Abstract][Full Text] [Related]
2. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Matson V; Fessler J; Bao R; Chongsuwat T; Zha Y; Alegre ML; Luke JJ; Gajewski TF
Science; 2018 Jan; 359(6371):104-108. PubMed ID: 29302014
[TBL] [Abstract][Full Text] [Related]
3. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN; Youngster I; Ben-Betzalel G; Ortenberg R; Lahat A; Katz L; Adler K; Dick-Necula D; Raskin S; Bloch N; Rotin D; Anafi L; Avivi C; Melnichenko J; Steinberg-Silman Y; Mamtani R; Harati H; Asher N; Shapira-Frommer R; Brosh-Nissimov T; Eshet Y; Ben-Simon S; Ziv O; Khan MAW; Amit M; Ajami NJ; Barshack I; Schachter J; Wargo JA; Koren O; Markel G; Boursi B
Science; 2021 Feb; 371(6529):602-609. PubMed ID: 33303685
[TBL] [Abstract][Full Text] [Related]
4. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B; Le Chatelier E; Derosa L; Duong CPM; Alou MT; Daillère R; Fluckiger A; Messaoudene M; Rauber C; Roberti MP; Fidelle M; Flament C; Poirier-Colame V; Opolon P; Klein C; Iribarren K; Mondragón L; Jacquelot N; Qu B; Ferrere G; Clémenson C; Mezquita L; Masip JR; Naltet C; Brosseau S; Kaderbhai C; Richard C; Rizvi H; Levenez F; Galleron N; Quinquis B; Pons N; Ryffel B; Minard-Colin V; Gonin P; Soria JC; Deutsch E; Loriot Y; Ghiringhelli F; Zalcman G; Goldwasser F; Escudier B; Hellmann MD; Eggermont A; Raoult D; Albiges L; Kroemer G; Zitvogel L
Science; 2018 Jan; 359(6371):91-97. PubMed ID: 29097494
[TBL] [Abstract][Full Text] [Related]
6. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.
Davar D; Dzutsev AK; McCulloch JA; Rodrigues RR; Chauvin JM; Morrison RM; Deblasio RN; Menna C; Ding Q; Pagliano O; Zidi B; Zhang S; Badger JH; Vetizou M; Cole AM; Fernandes MR; Prescott S; Costa RGF; Balaji AK; Morgun A; Vujkovic-Cvijin I; Wang H; Borhani AA; Schwartz MB; Dubner HM; Ernst SJ; Rose A; Najjar YG; Belkaid Y; Kirkwood JM; Trinchieri G; Zarour HM
Science; 2021 Feb; 371(6529):595-602. PubMed ID: 33542131
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome and immunotherapy response.
Burki TK
Lancet Oncol; 2017 Dec; 18(12):e717. PubMed ID: 29129446
[No Abstract] [Full Text] [Related]
8. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Sivan A; Corrales L; Hubert N; Williams JB; Aquino-Michaels K; Earley ZM; Benyamin FW; Lei YM; Jabri B; Alegre ML; Chang EB; Gajewski TF
Science; 2015 Nov; 350(6264):1084-9. PubMed ID: 26541606
[TBL] [Abstract][Full Text] [Related]
9. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park JS; Gazzaniga FS; Wu M; Luthens AK; Gillis J; Zheng W; LaFleur MW; Johnson SB; Morad G; Park EM; Zhou Y; Watowich SS; Wargo JA; Freeman GJ; Kasper DL; Sharpe AH
Nature; 2023 May; 617(7960):377-385. PubMed ID: 37138075
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive Probiotic
Gao G; Ma T; Zhang T; Jin H; Li Y; Kwok LY; Zhang H; Sun Z
Front Immunol; 2021; 12():772532. PubMed ID: 34970262
[TBL] [Abstract][Full Text] [Related]
12. The intimate relationship between gut microbiota and cancer immunotherapy.
Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
[TBL] [Abstract][Full Text] [Related]
14. Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma.
Voigt AY; Walter A; Young TH; Graham JP; Batista Bittencourt BM; de Mingo Pulido A; Prieto K; Tsai KY; Sundberg JP; Oh J
Exp Dermatol; 2023 Oct; 32(10):1624-1632. PubMed ID: 37350109
[TBL] [Abstract][Full Text] [Related]
15. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
16. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
17. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.
Peters BA; Wilson M; Moran U; Pavlick A; Izsak A; Wechter T; Weber JS; Osman I; Ahn J
Genome Med; 2019 Oct; 11(1):61. PubMed ID: 31597568
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma.
Limeta A; Ji B; Levin M; Gatto F; Nielsen J
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33268597
[TBL] [Abstract][Full Text] [Related]
19. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
Spencer CN; McQuade JL; Gopalakrishnan V; McCulloch JA; Vetizou M; Cogdill AP; Khan MAW; Zhang X; White MG; Peterson CB; Wong MC; Morad G; Rodgers T; Badger JH; Helmink BA; Andrews MC; Rodrigues RR; Morgun A; Kim YS; Roszik J; Hoffman KL; Zheng J; Zhou Y; Medik YB; Kahn LM; Johnson S; Hudgens CW; Wani K; Gaudreau PO; Harris AL; Jamal MA; Baruch EN; Perez-Guijarro E; Day CP; Merlino G; Pazdrak B; Lochmann BS; Szczepaniak-Sloane RA; Arora R; Anderson J; Zobniw CM; Posada E; Sirmans E; Simon J; Haydu LE; Burton EM; Wang L; Dang M; Clise-Dwyer K; Schneider S; Chapman T; Anang NAS; Duncan S; Toker J; Malke JC; Glitza IC; Amaria RN; Tawbi HA; Diab A; Wong MK; Patel SP; Woodman SE; Davies MA; Ross MI; Gershenwald JE; Lee JE; Hwu P; Jensen V; Samuels Y; Straussman R; Ajami NJ; Nelson KC; Nezi L; Petrosino JF; Futreal PA; Lazar AJ; Hu J; Jenq RR; Tetzlaff MT; Yan Y; Garrett WS; Huttenhower C; Sharma P; Watowich SS; Allison JP; Cohen L; Trinchieri G; Daniel CR; Wargo JA
Science; 2021 Dec; 374(6575):1632-1640. PubMed ID: 34941392
[TBL] [Abstract][Full Text] [Related]
20. The gut microbiota and immune checkpoint inhibitors.
Humphries A; Daud A
Hum Vaccin Immunother; 2018; 14(9):2178-2182. PubMed ID: 29494275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
